Want to know if cell therapy is right for your case?
A free consultation — the academic board reviews your history and recommends next steps without obligations.
About / 02
Since 2007 we have been turning stem cell research into clinical practice that helps patients across the globe. This page is about the scientific foundation behind every cell-therapy procedure we provide.
Foundations / 03
Beijing Han's United Biotechnology Co., Ltd. is one of China's leading regenerative medicine companies, focused on stem cell research and clinical application.
Our core technology is the isolation and use of stem cells from placenta and umbilical cord. This opens unique opportunities for treating a wide range of conditions across all ages — from cerebral palsy and autism to diabetes, heart and liver disease, and neurodegeneration.
Han's United concentrates on regenerative medicine — the science of restoring damaged tissues and organs. We pursue clinical practice alongside the development of new cell-based products, participate in international research projects and collaborate with leading institutes in France, China and beyond.
Ecosystem / 04
A group of companies covering the full cell-medicine cycle — from biomaterial isolation through clinical application and post-treatment support.
HAN's Bio
Storage and preparation of stem and immune cells. China's largest placental cell bank — holding 70% of the country's pediatric stem cells.
HAN's Pharmaceutical
Development and clinical trials of cell-based therapeutics. Eight first-class drugs with NMPA and ANSM clinical trial approvals.
HAN's Medical
Hanshi United tertiary multi-specialty hospital in Shangrao — clinical base for cell therapy and regenerative medicine.
Sino-Shenzhen
Health management, rejuvenation and anti-aging prevention programs based on cell-based regenerative medicine.
Living-cell advantage / 05
Frozen cells lose 30 to 40 percent of their activity after thawing. Freshly isolated cells retain 100 percent. This is the key scientific differentiator of our protocol.
We operate China's largest stem cell bank holding 70% of all pediatric stem cells in the country.
Direct partnerships with maternity hospitals secure a continuous supply of high-quality biological material.
Timeline / 06
Our full story spans nineteen years of accumulated work. Below are the milestones that turned laboratory discoveries into clinical practice.
Academician Han Zhongchao founds the company in Beijing to make advanced cell technologies accessible to patients.
Launch of the world's first placental stem cell bank — isolation, processing and long-term storage of biological material.
Establishment of the first academician work station and the Haizhi station — programs to attract international scientists.
The laboratory receives accreditation from the China National Accreditation Service (CNAS) — an internationally recognized standard.
Two first-class drugs receive clinical trial approvals from NMPA (China) and ANSM (France).
Launch of the International Cell Valley in Shangrao — two institutes, three centers and one production base.
The umbilical cord MSC injection drug receives NMPA approval for clinical trials in acute liver failure.
Hanshi United opens a new Beijing headquarters — the coordination center for the entire cell-medicine ecosystem.
The full 2007–2025 timeline will be published later.
Why trust / 07
Four pillars on which Han's United practice is built.
Built on the research of academician Han Zhongchao and an international team of scientists from France, China and beyond.
Only freshly isolated biologically active cells — never frozen, retaining full regenerative potential.
Protocols for patients of all ages: neurology, cardiology, endocrinology, autoimmune and other chronic conditions.
Laboratories certified to ISO 9001:2015, CMA and CNAS — guaranteeing safety and reproducibility.
Scientific board / 08
Eight scientists from France, China and partner institutes who took part in developing the cell-therapy methods used at Han's United. Not clinicians who treat patients, but the academic council that shapes the scientific foundation of our protocols.
Jacques CAEN
French Academy of Medicine, Academy of Technologies, Corresponding Member of the Academy of Sciences
Foreign member of the Chinese Academy of Engineering. President of the Sino-French Foundation for Science and Technology.
Bruno JARRY
President of the National Academy of Medicine of France
Former CNRS director, professor of genetics at the University of Strasbourg.
Jean-Pierre CAZENAVE
Member of the French Academy of Medicine
Emeritus professor of haematology and transfusion at the University of Strasbourg. 622 publications (Nature, NEJM, PNAS).
Jean-Francois STOLTZ
Professor of medicine at the University of Lorraine
Member of the French Academy of Medicine. Former INSERM U284, CNRS UMR 7563/7561.
Georges UZAN
Member of the French Academy of Medicine, director of INSERM U972
Expert in vascular stem cells. Recipient of the Friendship Award of China (2017).
Jean-Jacques LATAILLADE
Professor, director of the cell therapy centre at Percy Military Hospital (France)
Cell therapy, regenerative medicine, military medical research.
Raymond ASTRI
Senior engineer, big-data architecture
Fortune 500 experience: IBM, SCHNEIDER ELECTRIC. Digital infrastructure for medical platforms.
Constantin AGOURIDAS
Professor at ENSCP, chief expert at IMCELL Lab
Former director of drug development at Sanofi-Aventis, R&D director at L'Oréal cosmetics.
Scientific director — academician Han Zhongchao (h-index 81, member of the French National Academy of Medicine). The full profile is in preparation.
A free consultation — the academic board reviews your history and recommends next steps without obligations.
We use cookies and analytics services to improve the website experience. Privacy Policy